8-K Announcements
6Material company update
May 13, 2026·SEC
Material company update
Mar 19, 2026·SEC
Material company update
Mar 2, 2026·SEC
Acrivon Therapeutics, Inc. Common Stock(ACRV)Earnings, Financials & Key Ratios
ACRV•NASDAQ
$1.68
Price updated Jun 27, 2026
AboutAcrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in a potentially registrational Phase 2 trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response and cell cycle regulation pathways, such as WEE1, a protein kinase and PKMYT1, a protein serine/threonine kinase. The company was incorporated in 2018 and is based in Watertown, Massachusetts.Show more
- Revenue$0
- EBITDA-$83M+6.2%
- Net Income-$78M+3.3%
- EPS (Diluted)-2.02+3.8%
- ROE-53.86%+0.4%
ACRV Price & Volume
Acrivon Therapeutics, Inc. Common Stock (ACRV) stock price & volume — 10-year historical chart
Loading chart...
Clinical Pipeline Development Drives Sustained Cash Burn
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial Position:Adequate
Cash Flow:Burning
Primary Risk:Clinical trial execution failure
"Acrivon Therapeutics remains a high-risk, clinical-stage entity whose valuation is tethered to the success of its AP3 proteomic platform rather than commercial performance. While the company maintains a current ratio of 8.98, the lack of revenue and consistent quarterly net losses, which reached $19.0M in 2026Q1, necessitate ongoing external capital raises. Investors should monitor the company's ability to navigate the complexities of its companion diagnostic-linked drug development, as the current asset base is almost entirely devoid of tangible value beyond $6.9M in net PPE."
Verdict Logic
the company's reliance on external capital to fund operations is underscored by a consistent quarterly cash burn that reached $20.6M in 2026Q1 and a lack of commercial revenue to offset R&D intensity.
ACRV Growth Metrics
Acrivon Therapeutics, Inc. Common Stock (ACRV) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM7.74%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM9.91%
Return on Capital
10 Years-69.43%
5 Years-43.01%
3 Years-53.61%
Last Year-57.33%
ACRV Recent Earnings
Acrivon Therapeutics, Inc. Common Stock (ACRV) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)
Q2 2026Latest
May 13, 2026Metric
Actual
Est
EPS
$0.49+0.0%
$0.49
Rev
—
$277,167
Q2 2026
Mar 19, 2026Metric
Actual
Est
EPS
$0.49+0.0%
$0.49
Rev
—
$166,286
Q4 2025
Nov 13, 2025Metric
Actual
Est
EPS
$0.47+17.5%
$0.57
Rev
—
—
Q3 2025
Aug 13, 2025Metric
Actual
Est
EPS
$0.55+3.5%
$0.57
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 13, 2026 | $0.49vs $0.49+0.0% | —vs $277,167 |
| Q2 2026 | Mar 19, 2026 | $0.49vs $0.49+0.0% | —vs $166,286 |
| Q4 2025 | Nov 13, 2025 | $0.47vs $0.57+17.5% | — |
| Q3 2025 | Aug 13, 2025 | $0.55vs $0.57+3.5% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Acrivon Therapeutics, Inc. Common Stock (ACRV)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.68 | $53.01M | -0.83 | — | — | -53.86% | — | |
| $17.23 | $2.22B | 8.32 | 20.38% | 99.97% | 64.48% | — | |
| $108.12 | $8.83B | -29.30 | -16.72% | -612.17% | -25.02% | — | |
| $31.47 | $3.66B | -36.17 | 48.29% | -188.15% | -41.54% | — | |
| $327.79 | $9.47B | -24.32 | -100% | — | -43.02% | — | |
| $38.85 | $7.98B | -14.03 | — | — | -68.16% | — |
Compare ACRV vs Peers
Acrivon Therapeutics, Inc. Common Stock (ACRV) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ACRV SEC Filings & Documents
Acrivon Therapeutics, Inc. Common Stock (ACRV) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when ACRV posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ACRV Frequently Asked Questions
Acrivon Therapeutics, Inc. Common Stock (ACRV) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is ACRV profitable?
Acrivon Therapeutics, Inc. Common Stock (ACRV) reported a net loss of $77.3M for fiscal year 2025.
Dividend & Returns
What is ACRV's return on equity?
Acrivon Therapeutics, Inc. Common Stock (ACRV) has a return on equity (ROE) of -53.9%. Negative ROE indicates the company is unprofitable.
What is Acrivon Therapeutics, Inc. Common Stock's free cash flow?
Acrivon Therapeutics, Inc. Common Stock (ACRV) had negative free cash flow of $66.3M in fiscal year 2025, likely due to heavy capital investments.